On 12 October 2022, Knowledge Ecology International (KEI) published a briefing note on the U.S. federal government FAR 52.227-1 authorizations (for non voluntary use of patents) disclosed in 166 SEC exhibits. KEI Briefing Note 2022:2, Federal government FAR 52.227-1 authorizations… Continue Reading
On Tuesday, 27 September 2022, Knowledge Ecology International (KEI) delivered the following oral statement during discussions on patents and health at the 34th session of the WIPO Standing Committee on the Law of Patents (SCP). In July 2022, KEI published… Continue Reading
As part of ongoing WHO negotiations on a pandemic treaty, the WHO secretariat is set to convene four informal, focused consultations (IFCs) on the following themes: 1) legal matters, 2) operationalizing and achieving equity, 3) intellectual property and access to… Continue Reading
On Thursday, 7 July 2022, the 40th session of the Human Rights Council (HRC) adopted, by consensus, a resolution on Access to medicines, vaccines and other health products in the context of the right of everyone to the enjoyment of… Continue Reading
Since the COVID 19 Pandemic began, there has been a spirited debate over patent rights, including a highly publicized 20 month debate over a proposed WTO waiver on intellectual property rights. During that time a handful of countries have taken… Continue Reading
On Friday, 15 July 2022 Knowledge Ecology International delivered the following opening statement at the 2022 WIPO General Assembly. The COVID pandemic illustrates flaws in the intellectual property system. In a public health crisis, no company should have a monopoly… Continue Reading
This is a letter to Roche requesting a voluntary license to the patents on risdiplam, a treatment for Spinal Muscular Atrophy (SMA). KEI-Risdiplan-patent-license-request-8july2022 This was the August 5, 2022 response from Roche. Roche-Response-to-Risdiplam-license-request–5Aug2022 KEI wrote to Roche again on February… Continue Reading
Risdiplam, originally developed under contract with the SMA Foundation by PTC Therapeutics and licensed to Roche for sale under the brand name Evrysdi, is a medication used to treat spinal muscular atrophy and the first oral medication approved to treat… Continue Reading